Centessa Pharmaceuticals (NASDAQ:CNTA) Rating Lowered to Hold at Needham & Company LLC

Centessa Pharmaceuticals (NASDAQ:CNTA) was downgraded by investment analysts at Needham & Company LLC from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday, Marketbeat.com reports.

Several other equities analysts also recently commented on the stock. Wolfe Research initiated coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, February 24th. They set an “outperform” rating and a $40.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 21st. Chardan Capital reaffirmed a “buy” rating and set a $30.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, January 2nd. B. Riley Financial increased their price objective on Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, December 1st. Finally, TD Cowen reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 14th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Centessa Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $40.00.

Centessa Pharmaceuticals Stock Up 0.4%

Shares of NASDAQ CNTA opened at $39.86 on Tuesday. The firm’s fifty day moving average is $26.62 and its 200 day moving average is $25.35. Centessa Pharmaceuticals has a 52 week low of $9.60 and a 52 week high of $40.26. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. The company has a market cap of $5.82 billion, a price-to-earnings ratio of -21.78 and a beta of 1.25.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Monday, April 6th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.10). On average, equities research analysts expect that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, insider Karen M. Anderson sold 120,029 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the completion of the transaction, the insider directly owned 62,085 shares in the company, valued at approximately $1,629,731.25. This trade represents a 65.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Iqbal J. Hussain sold 38,951 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total value of $979,617.65. Following the completion of the sale, the insider directly owned 57,645 shares in the company, valued at approximately $1,449,771.75. This represents a 40.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 349,073 shares of company stock valued at $9,429,412. Corporate insiders own 7.09% of the company’s stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. American Century Companies Inc. increased its position in shares of Centessa Pharmaceuticals by 3.5% during the second quarter. American Century Companies Inc. now owns 1,130,708 shares of the company’s stock valued at $14,858,000 after acquiring an additional 37,954 shares in the last quarter. Royce & Associates LP purchased a new position in Centessa Pharmaceuticals in the 3rd quarter worth approximately $5,999,000. Eagle Health Investments LP bought a new position in Centessa Pharmaceuticals in the 3rd quarter valued at approximately $2,500,000. Foresite Capital Management VI LLC boosted its stake in Centessa Pharmaceuticals by 4.8% during the 3rd quarter. Foresite Capital Management VI LLC now owns 1,314,019 shares of the company’s stock valued at $31,865,000 after purchasing an additional 60,640 shares during the last quarter. Finally, Federated Hermes Inc. purchased a new stake in Centessa Pharmaceuticals during the 3rd quarter valued at $42,429,000. 82.01% of the stock is owned by institutional investors.

Key Stories Impacting Centessa Pharmaceuticals

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Eli Lilly agreed to acquire Centessa in a deal worth up to $7.8 billion (initial $38.00/share cash plus contingent value rights), which creates a takeover premium and is the primary driver of the stock’s upward move. Eli Lilly to buy Centessa Pharma
• Positive Sentiment: Leerink Partners reaffirmed a “market perform” rating and raised its price target to $40.00, a small upward revision that supports the view the deal price is appropriate. Leerink raises price target
• Neutral Sentiment: Unusual options activity: earlier spikes in call buying and, more recently, a large surge in put purchases (10,659 puts) signal mixed positioning—some traders betting on deal completion/arb, others hedging or speculating on downside. (No single article link)
• Negative Sentiment: Multiple brokerages downgraded CNTA (Needham, Wolfe Research, Stephens), citing valuation or deal-related uncertainty — analyst downgrades can weigh on momentum despite the takeover premium. Needham downgrades
• Negative Sentiment: Several law firms and shareholder groups have announced investigations into whether the sale process and price are fair (Monteverde, Kahn Swick & Foti, Ademi, Halper Sadeh). Potential litigation or challenges to the transaction could delay closing or pressure the spread between market price and deal consideration. Shareholder investigation announced
• Negative Sentiment: Recent quarterly results missed EPS estimates (reported ($0.48) vs. consensus ($0.38)), underscoring ongoing clinical and execution risks outside the transaction context. Centessa earnings miss

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.